Post by
francoisl13 on Nov 05, 2024 1:33pm
I wonder....
...if KNE set the expectations to high (again) for Q4...here's what they are targeting for Q4/2024 (from their September presentation):
1. Financing announcement
2. Potential M&A announcement
3. Announce distribution agreements outside of North America - (done for some part of the world)
4.Obtain clearance from Health Canada on revyve Antimicrobial Wound Gel - (didn't see any official announcement)
5.Launch revyve Antimicrobial Wound Gel Spray
6.Commence DispersinB University of Miami Clinical Trial
It is Nov.5th...I wonder if any of the above will happen in Q4 considering that we're basically left with only 5-6 weeks before the Holidays and very little of the above have been confirmed and announced.
I understand that KNE is in a highly supervised and reglemented market but, setting up the expectations and then not meeting them is not doing any good to the company reputation especially with the investment community.
As I said many times, I like this company product lines and the way they are managing it but, not their 'bat average' in regards to meeting expectations they are setting up themself...
GLTA!
Comment by
RoyMax123 on Nov 12, 2024 1:26pm
No 2 is done, so most likely No 1 will be announced shortly.
Comment by
francoisl13 on Nov 12, 2024 1:51pm
Very good news. We are expanding our product line, we are expanding our geographic footprint and all that at a, what seems, to be a decent cost. The most important part of it is that Dr. Francesco Bellini is behind FB Dermatology, he is a 'legend' ! I hope they will find him a spot on our board...if he wants to join it would be a major acquisition for KNE. GLTA!
Comment by
KevinOleary on Nov 12, 2024 2:41pm
The expectations that you don't like are really the estimates of how long it will take for the FDA to get it's act together and allow the acne and dispersin trials to start. kne does not control the FDA in any way, so it's a wait and see game to see what new ideas the eggheads at the FDA come up with to roadblock the start.